|MolMed S p A -- Germany Stock|| |
EUR 0.46 0.0335 6.79%
Dr. Maurizio Tassi serves as a NonExecutive Director of Molecular Medicine S.p.A. since November 6 2007. He was a Member of the Audit and Risk Management Committee of the Company since November 6 2007. He has worked for 20 years in the investment banking sector for various companies including NewSmith Capital Partners Citigroup Schroders and CredianstaltBankverein and specialized in capital markets and capital increases. He has experience in the pharmaceutical sector. He was involved in the privatization of Gedeon Richter in Hungary in the dual listing in Switzerland and North America of Biomarin Pharmaceuticals and Amplifon. He also serves as Sole Director of Tassi Limited. He gained a degree in Anthropology from the University of London and a MS in Economics from the University of London.
Age: 54 Director Since 2007
39 02 21 27 71 http://www.molmed.com
The company has return on total asset (ROA)
of (18.1) %
which means that it has lost $18.1 on every $100 spent on asset. This is way below average. Similarly, it shows return on equity (ROE)
of (61.21) %
meaning that it generated substantial loss on money invested by shareholders.
The company has accumulated 964 K in total debt with debt to equity ratio (D/E) of 6.1 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. MolMed S p A has Current Ratio of 1.37 which is within standard range for the sector.
MolMed S.p.A., a medical biotechnology company, focuses on the research, development, and clinical validation of anticancer therapies. MolMed S.p.A. was founded in 1996 and is headquartered in Milan, Italy. MolMed S is traded on Frankfurt Stock Exchange in Germany.MolMed S p A (4HW) is traded on Frankfurt Stock Exchange in Germany. It is located in Via Olgettina, 58 and employs 23 people.